

References

I-29

1. Becker MA. Prevention of recurrent gout: Pharmacologic urate-lowering therapy and treatment of tophi. UpToDate Inc., Waltham, MA. Last reviewed January 2016.
2. American College of Rheumatology. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Accessed April 21, 2017.
3. Krystexxa[®] (pegloticase) for intravenous infusion [package insert]. Horizon Therapeutics USA, Inc. Lake Forest, IL.; Revised 01/2020.
4. Calabrese LH, Kavanaugh A, Yeo AE, Lipsky PE. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. *Arthritis Res Ther.* 2017;19:191.
5. Cunha RN, Aguiar R, Farinha F. Impact of pegloticase on patient outcomes in refractory gout: Current perspectives. *Rheumatology: Research & Reviews.* 2018;10:141-149.
6. Schlesinger N, Edwards NL, Yeo AE, et. al.. Development of a multivariable improvement measure for gout. *Arthritis Research & Therapy.* 2020;22(1):1-10.
7. Clinical Pharmacology[™] 2020. Tampa FL: Gold Standard, Inc. Pegloticase.
8. Micromedex DrugDex Compendium[®]. 2020. Pegloticase (Krystexxa).